glp-1 receptor agonist drugs in development research Mapping the effectiveness and risks of agonists Trends in the Development of

It is a monosaccharide, which means it is a single sugar molecule

It acts as a bispecific molecule, combining GLP-1 receptor agonism with GIP receptor antagonism to promote weight loss

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.

The search for over-the-counter GLP-1 alternatives reflects growing interest in weight loss support

Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing